Bone marrow transplantation
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.
Iman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, Jaime Sanz, Anne Huynh, Nicolaus Kröger, Eva Maria Wagner-Drouet, David Burns, Matthias Eder, Bruno Lioure, Depei Wu, Jiri Mayer, Kristina Carlson, Matthias Stelljes, Matthew Collin
Published: 202510.1038/s41409-025-02765-1
Abstract
Mutations in the DNMT3A gene are not yet classified as a distinct prognostic group in the latest European Leukemia Net (ELN) 2022 genetic risk classification of AML. We analyzed 1888 adult AML patients with ELN 2022 intermediate- or poor-risk cytogen…
Preview only. Read the full abstract at the source